Ballentine Partners’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Ballentine Partners’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,787	Closed	-$56.4K	–	646
2023 Q1	$56.4K	Hold	4,787	–	–	﹤0.01%	558
2022 Q4	$68.9K	Hold	4,787	–	–	﹤0.01%	497
2022 Q3	$240K	Hold	4,787	–	–	0.01%	398
2022 Q2	$408K	Hold	4,787	–	–	0.01%	268
2022 Q1	$722K	Hold	4,787	–	–	0.02%	212
2021 Q4	$1.43M	Hold	4,787	–	–	0.04%	142
2021 Q3	$1.87M	Buy	+4,787	New	+$2.04M	0.06%	103

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Ballentine Partners's FNCH Position: Q2 2023 in Review

Ballentine Partners sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 4,787 shares — an estimated $56.4K sold.

Ballentine Partners first reported a position in FNCH in Q3 2021 and held it in 7 quarters. The position peaked at $1.87M in Q3 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Ballentine Partners reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ballentine Partners sold 4,787 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $56.4K.
Ballentine Partners first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Ballentine Partners's Finch Therapeutics Group, Inc. Common Stock position peaked at $1.87M in Q3 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Ballentine Partners's 13F filing for Q2 2023, filed 26 Jul 2023.